利拉鲁肽联合二甲双胍治疗肥胖型2型糖尿病的疗效及代谢指标分析

Analysis of the Efficacy and Metabolic Index of Liraglutide Combined with Metformin in the Treatment of Obese Type 2 Diabetes

目的分析利拉鲁肽联合二甲双胍治疗肥胖型2型糖尿病的疗效及氧化应激指标。方法选取2020年1月—2021年5月该院收治的肥胖型2型糖尿病患者72例,随机分组,研究组(n=36)采用利拉鲁肽联合二甲双胍治疗,对照组(n=36)采用二甲双胍治疗,比较两组的治疗效果及氧化应激指标,血脂指标,血糖水平、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)。结果研究组血脂水平、血糖水平、HbA1c、HOMA-IR均低于对照组,差异有统计学意义(P<0.05);研究组氧化应激指标改善情况优于对照组,差异有统计学意义(P<0.05);研究组治疗有效率高于对照组,差异有统计学意义(P<0.05)。结论二甲双胍作为治疗2型糖尿病的一线药物,具有良好的性价比和作用。利拉鲁肽是一种人胰高糖素样肽-1(GLP-1)类似物,它通过促进胰岛素释放,抑制胰高血糖素分泌,提高外周组织胰岛素敏感性,降血糖效果肯定。利拉鲁肽联合二甲双胍治疗肥胖型2型糖尿病的疗效确切,可以降低血糖、HbA1c、HOMA-IR等水平,治疗效果显著,有效改善氧化应激,具有临床应用的价值。

Objective To analyze the efficacy and oxidative stress indicators of liraglutide combined with metformin in the treatment of obese type 2 diabetes. Methods From January 2020 to May 2021, 72 patients with obese type 2 diabetes admitted to the hospital were selected for randomization. The study group(n=36) was treated with liraglutide combined with metformin, and the control group(n=36) was treated with metformin. The treatment effects and oxidative stress indicators,lipid index, blood glucose levels, glycosylated hemoglobin(HbA1c), and insulin resistance index(HOMA-IR) were compared between the two groups. Results The blood lipid level, blood glucose level, HbA1c and HOMA-IR of the study group were lower than those of the control group, and the difference was statistically significant(P<0.05). The improvement of oxidative stress indicators in the study group was better than that in the control group, and the difference was statistically significant(P<0.05). The effective rate of treatment in the study group was higher than that in the control group, and the difference was statistically significant(P <0.05). Conclusion As a first-line drug for the treatment of type 2 diabetes,metformin has a good cost performance and effect. Liraglutide is an analog of human glucagon-like peptide-1(GLP-1). It promotes insulin release, inhibits glucagon secretion, improves insulin sensitivity in peripheral tissues, and has a positive effect on lowering blood glucose. Liraglutide combined with metformin has a definite therapeutic effect in the treatment of obese type 2 diabetes. It can reduce blood glucose, HbA1 c, HOMA-IR and other levels. The therapeutic effect is significant, and it can effectively improve oxidative stress. It has clinical application value.